METHOD FOR EVALUATING CLINICAL EFFECTIVENESS AND DYNAMICS OF DESTRUCTIVE CHANGES IN PULMONARY TISSUE ACCOMPANYING PULMONARY TUBERCULOSIS Russian patent published in 2012 - IPC G01N33/53 G01N33/49 

FIELD: medicine.

SUBSTANCE: peripheral blood is analysed for a percentage of CD62L^-CD27^- lymphocytes as related to total CD4⁺ lymphocytes by peripheral blood cell treatment with mixed monoclonal antibodies specific to CD4, CD62L, CD27 markers followed by cell analysis by flow cytometry technique. The analysis is conducted in the beginning of and during treatment. If observing the decreased original percentage of CD62L-CD27 lymphocytes during tuberculosis treatment, terminated (reduced) destructive processes in pulmonary tissue, positive dynamics and clinical effectiveness are stated. The absence of the varying percentage of CD62L^-CD27^- lymphocytes during treatment with underlying high value testifies to the absence of positive dynamics, continuing pulmonary destruction and a low response to treatment. The increasing percentage of CD62L^-CD27^- lymphocytes is an indicator of progressing tuberculosis, rising destructive processes in pulmonary tissue and the absence of clinical effectiveness.

EFFECT: use of the method ensures monitoring of tuberculosis treatment, objective evaluation of clinical effectiveness and dynamics of pathological changes in pulmonary tissue.

4 ex